

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 63 (2007) 1560-1567

Synthesis of a series of novel 2',3'-dideoxy-6',6'-difluoro-3'-thionucleosides

Xuyi Yue,^a Yun-Yun Wu^a and Feng-Ling Qing^{a,b,*}

^aKey Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, Shanghai 200032, China

^bInstitute of Biological Sciences and Biotechnology, Donghua University, 2999 North Renmin Lu, Shanghai 201620, China

Received 5 September 2006; revised 7 December 2006; accepted 8 December 2006 Available online 26 December 2006

Abstract—A series of novel 2',3'-dideoxy-6',6'-difluoro-3'-thionucleosides **1a**–**d**, analogues of 3TC that has high biological activities against HIV and HBV, have been synthesized from the *gem*-difluorohomoallyl amine **7** in a straightforward fashion. Our synthesis featured the construction of thiofuranose skeleton through ring closure of key intermediates and installation of pyrimidine ring with amino group in compounds **13a**,**b**.

© 2006 Elsevier Ltd. All rights reserved.

1. Introduction

2',3'-Dideoxynucleosides (ddNs) have far proven to be the most effective therapeutic agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).¹ Among them, 3'-azido-2',3'-dideoxythymidine (AZT),² 2',3'-dideoxyinosine (DDI),³ and 2', 3'-dideoxycytidine (DDC)⁴ have been approved for the treatment of AIDS. In spite of the initial success obtained with these modified nucleosides, the instability of the glycosidic bond of the 4'-oxonucleosides under physiological conditions⁵ as well as undesirable side effects of certain nucleosides has prompted the search for further novel nucleosides with improved biological and chemical properties. Consequently, extensive modifications have been made to both the heterocyclic base and the sugar moiety of nucleosides.⁶ Sulfur-containing dideoxynucleosides, (-)- β -L-(2R,5S)-1,3-oxathiolanylcytosine $(3TC)^7$ and its 5-fluorocytosine analogue (-)-FTC (Fig. 1),⁸ showed higher biological activity than conventional ddNs and were approved by the FDA for the treatment of HIV infection. As the *gem*-diffuoromethylene (CF_2) group has been suggested by Blackburn as an isopolar and isosteric substituent for oxygen,9 recently we have designed and synthesized a new difluoromethylenated thionucleoside A.¹⁰ To investigate the structure-activity relationship of this novel analogue of 3TC, a series of 2',3'-dideoxy-6',6'-difluoro-3'-thionucleosides are needed. Herein, we wish to report the preparation of stereoisomers 1c and 1d of compound A (Fig. 1).





Figure 1.

2. Results and discussion

On the basis of our retrosynthetic analysis (Scheme 1), the target molecules 1a-d can be reached from the *gem*-difluoromethylenated cyclic amine **B** by installing the pyrimidine base moiety at C1 position through the reported methodology.¹¹As the *gem*-difluoromethylenated thiofuranose could be smoothly constructed via ring closure of the corresponding dimesylate,¹² we envisioned that the *gem*-difluoromethylenated diols **C** could be suitable precursors for **B**. Compounds **C** could be afforded by removal of the isopropylidene ketal of intermediate **D** followed by oxidation of the dihydroxyl moiety and subsequent reduction. Conversion of hydroxyl group of homoallyl alcohol **E** to amino group followed by dihydroxylation would furnish the amino alcohol **D**. To obtain the desired base configuration of target nucleosides

Keywords: gem-Difluoromethylenated compounds; Thionucleoside.


^{*} Corresponding author. Fax: +86 21 64166128; e-mail: flq@mail.sioc. ac.cn



Scheme 1. Retrosynthetic analysis of target molecules 1a-d.

1a–d, the configuration of amino group (C3 position) of compound **D** must be *R* and thus the hydroxyl group of homoallyl alcohol **E** should be formed with *S* configuration. We have reported that the allylation of chiral aldehyde with 3-bromo-3,3-difluoropropylene in the presence of indium provided the *anti*-isomer of homoallyl alcohol as the major product.¹³ Therefore, (*S*)-glyceraldehyde acetonide **2** was chosen for the preparation of the desired *gem*-difluoromethylenated homoallyl alcohol **E**.

Accordingly, the coupling of 1-(*S*)-glyceraldehyde acetonide **2** with 3-bromo-3,3-difluoropropene in DMF in the presence of indium provided *gem*-difluorohomoallyl alcohol **3** in 73% yield. The ratio of *anti/syn* is 8.1:1 determined by ¹⁹F NMR. Notably, *anti*-**3** was our desired compound (Scheme 2). Then, reaction of compound **3** with Tf₂O in CH₂Cl₂ at -25 °C gave triflate **4**. Subsequent treatment of




Scheme 2. Reagents and conditions: (a) In powder, CH_2 =CHCF₂Br, DMF, 22 h, 73%; (b) Tf₂O, pyridine, CH_2Cl_2 , -25 °C, 1 h, 92%; (c) NaN₃, DMF, 12 h, rt, overnight, 75%; (d) (i) Ph₃P, THF, rt, 6 h; (ii) H₂O, 50 °C, 40 h, 57%; (e) Boc₂O, Et₃N, THF, CH₂Cl₂, 94%.


compound 4 with NaN₃ in DMF provided azide 5. Reduction of compound 5 with Ph₃P in THF produced our desired amine *syn*-6, which could be easily separated through column chromatography. Finally, protection of amine *syn*-6 with Boc₂O gave amide 7 in 94% yield.

With the diffuorohomoallyl amide 7 in hand, key intermediates 13a and 13b were synthesized in a straightforward fashion (Scheme 3). The Os-catalyzed dihydroxylation of compound 7 gave a mixture of the diastereoisomers 8a and **8b** in 83% yield (**8a/8b**=1:1). Luckily, the diastereoisomers 8a and 8b were easily separated by column chromatography. Benzoates 9a and 9b were obtained by selective benzoylation of the primary hydroxyl groups of diols 8a and 8b, respectively. The conversions of benzoates 9a and 9b to their respective difluoromethylenated furanoses 10a and 10b were achieved by the following two steps: (1) the acidic hydrolysis of the isopropylidene groups by treatment with 75% aqueous AcOH at 50 °C and (2) the oxidative scission of the resulting diols with NaIO₄ and subsequent cyclization. Difluorinated furanoses 10a and 10b were directly reduced by NaBH₄ in MeOH to give the diols **11a** and **11b** both in 77% yields from 9a and 9b, respectively. Mesylations at C1 and C4 positions of diols 11a and 11b, followed by treatment with Na₂S in DMF, resulted in a ring closure to provide thiofuranoses 12a and 12b as single stereoisomers, respectively. Finally, removal of Boc group of thiofuranoses 12a and 12b gave the key intermediates 13a and 13b in high vields, respectively.

The construction of pyrimidine was followed by the procedure reported by Shaw and Warrener (Scheme 4).¹¹ Condensation of amines **13a** and **13b** with 3-ethoxy-2-propenoyl



Scheme 3. Reagents and conditions: (a) OsO_4 , NMNO, acetone, H_2O , 48 h; (b) BzCl, pyridine, CH_2Cl_2 , -78 °C, 2 h; (c) (i) AcOH (aq 75%), 50 °C, 3 h; (ii) $NaIO_4$, H_2O , rt, 3 h; (d) $NaBH_4$, MeOH, 0 °C, 20 min; (e) (i) MsCl, pyridine, 0 °C–rt, overnight; (ii) $Na_2S \cdot 9H_2O$, DMF, 80 °C, 10 min; (f) CF_3CO_2H , CH_2Cl_2 , rt, 15 min.



Scheme 4. Reagents and conditions: (a) 3-ethoxy-2-propenoyl isocyanate, DMF, benzene, -25 °C, overnight; (b) 2 N H₂SO₄, reflux, 3 h; (c) satd NH₃/MeOH, rt, overnight; (d) (i) Ac₂O, pyridine, DMAP, rt, 12 h; (ii) TPSCl, DMAP, Et₃N, rt, 4 h; (iii) concd NH₃·H₂O, rt, overnight.

isocyanate in DMF at -25 °C gave the compounds **14a** and **14b** followed by ring closure with 2 N H₂SO₄ in dioxane to afford the compounds **15a** and **15b**, respectively. Deprotection of the compounds **15a** and **15b** was accomplished by ammonolysis to give the corresponding 2',3'-dideoxy-6',6'-difluoro-3'-thiouridine **1a** and **1b**. Thiouridines **1a** and **1b** were further converted into the cytosine derivatives **1c** and **1d**, respectively, by isopropylbenzene-sulfonylation of the O-4 position followed by treatment with concentrated NH₃ · H₂O.

The absolute configuration of the target molecules 1a-d was assigned on the basis of the X-ray crystal structures of compounds 1a,b (Fig. 2).¹⁴

In summary, based on the bioisosteric rationale, we have synthesized a series of 2',3'-dideoxy-6',6'-difluoro-3'-thio-nucleosides. Our synthesis featured the construction of thio-furanose skeleton through ring closure of key intermediates and construction of pyrimidine ring with amino group in compounds **13a,b**. Antiviral and cytotoxicity evaluations of herein synthesized 2',3'-dideoxy-6',6'-difluoro-3'-thio-nucleosides **1a**-**d** are currently in progress.

3. Experimental section

3.1. General

Tetrahydrofuran (THF) was distilled from sodium metal. Dichloromethane (CH_2Cl_2) and pyridine were distilled from

CaH₂. ¹H NMR spectra were recorded on a Bruker AM300 spectrometer. ¹⁹F NMR spectra were recorded on a Bruker AM300 spectrometer (FCCl₃ as external standard and low field is positive). All the melting points and optical rotations are uncorrected. The following abbreviations were used to explain the multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet.

3.1.1. 1-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2,2-difluoro-but-3-en-1-ol (3). A suspension consisting of an aldehyde 2 (9.900 g, 76.15 mmol), 3-bromo-3,3-difluoropropene (17.100 g, 108.92 mmol), powdered indium (9.700 g, 84.49 mmol), and DMF (500 mL) was stirred for 22 h at room temperature. The reaction mixture was then quenched with 1 N HCl and extracted with ether. The combined organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=3:1) to give 11.500 g (72.6% yield) of compound **3** as a clear oil: ¹H NMR $(300 \text{ MHz}, \text{ CDCl}_3) \delta 6.12-5.94 \text{ (m, 1H)}, 5.74 \text{ (dt,}$ J=17.4 Hz, 2.7 Hz, 1H), 5.60 (d, J=11.1 Hz, 1H), 4.33-4.27 (m, 1H), 4.06-3.99 (m, 3H), 2.38 (s, 1H), 1.44 (s, 3H), 1.37 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ –106.36 (dm, J=253.8 Hz, 0.11F), -108.01 (dm, J=250.0 Hz, 0.89F), -110.23 (dm, J=256.6 Hz, 0.89F), -111.29 (dm, J=248.2 Hz, 0.11F); IR (thin film) ν_{max} 3444, 1652, 1219 cm^{-1} ; MS *m/z* 209 (M⁺+1, <1), 193 (14), 101 (77), 43 (100). Anal. Calcd for C₉H₁₄O₃F₂: C, 51.92; H, 6.78. Found: C, 51.45; H, 6.72.




Figure 2. ORTEP drawing of the X-ray crystallographic structures of compounds 1a and 1b.

3.1.2. Trifluoromethanesulfonic acid 1-(2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-difluorobut-3-enyl ester (4). Compound 3 (10.000 g, 48.08 mmol) was dissolved in dry CH₂Cl₂ (144 mL), after that freshly distilled pyridine (7.8 mL, 96.21 mmol) was added. The resulting mixture was cooled to -35 °C. Then, trifluoromethanesulfonic anhydride (12.1 mL, 72.12 mmol) was added dropwise to the solution with stirring. After that, the reaction mixture was stirred for about 1 h at about -25 °C. Water and NaHCO₃ solution were added successively after the mixture was warmed to the room temperature. Then the mixture was extracted with CH₂Cl₂, dried over anhydrous Na₂SO₄, and purified by silica gel column chromatography (petroleum ether/ethyl acetate=8:1) to afford compound 4 (15.000 g, 91.8% yield) as a clear oil: ¹H NMR (300 MHz, CDCl₃) δ 6.02–5.82 (m, 2H), 5.73-5.70 (m, 1H), 5.20-5.12 (m, 1H), 4.41 (td, J=6.9 Hz, 2.7 Hz, 1H), 4.08-3.93 (m, 2H), 1.45 (s, 3H), 1.37 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ -74.1 (s, 3F), -102.19 (dm, J=269.9 Hz, 0.06F), -106.38 (dm, J=254.1 Hz, 0.94F), -107.29 (dm, J=219.7 Hz, 0.94F), -108.41 (dm, J=265.1 Hz, 0.06F); IR (thin film) v_{max} 1421, 1214, 1143 cm⁻¹; MS *m*/*z* 325 (M⁺-CH₃, 24), 101 (12), 77 (14), 43 (100). Anal. Calcd for C₁₀H₁₃O₅F₅S: C, 35.30; H, 3.85. Found: C, 35.23; H, 3.83.

3.1.3. 4-(1-Azido-2.2-difluoro-but-3-envl)-2.2-dimethvl-[1,3]dioxolane (5). A solution of compound 4 (15.000 g. 44.12 mmol) in DMF (120 mL) was cooled to 0 °C in an ice bath. Then, sodium azide (13.192 g, 202.95 mmol) was added carefully with stirring. The reaction mixture was stirred overnight at room temperature. Water was added to quench the reaction. The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄, and concentrated in vacuo. The residue was quickly purified by silica gel column chromatography (petroleum ether/ethyl acetate=8:1) to afford compound 5 (7.700 g, 74.9% yield): clear oil, ¹H NMR (300 MHz, CDCl₃) δ 6.06–5.92 (m, 1H), 5.81–5.73 (m, 1H), 5.60 (d, J=11.1 Hz, 1H), 4.32– 4.26 (m, 1H), 4.13-4.08 (m, 1H), 3.91-3.85 (m, 1H), 3.57-3.51 (m, 1H), 1.47 (s, 3H), 1.40 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ -99.84 (dm, J=253.5 Hz, 0.95F), -103.70 (dm, J=252.7 Hz, 0.05F), -106.07 (dm, J=249.6 Hz, 0.05F), -106.62 (dm, J=253.8 Hz, 0.95F); IR (thin film) v_{max} 2120, 1263, 1216, 1065 cm⁻¹; MS m/z 218 (M⁺-CH₃, 41), 101 (49), 77 (16), 43 (100). Anal. Calcd for C₉H₁₃O₂F₂N₃: C, 46.35; H, 5.62; N, 18.02. Found: C, 46.69; H, 5.79; N, 17.72.

3.1.4. 1-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-2,2-difluorobut-3-enylamine (6). A solution of Ph₃P (14.701 g, 56.05 mmol) in THF (20 mL) was slowly added at room temperature to a solution of compound **5** (7.700 g, 33.05 mmol) in THF (93 mL), and then, the reaction mixture was monitored by TLC. When the starting material was completely consumed, water (70 mL) was added and the reaction mixture was stirred for 40 h at 50 °C. The reaction mixture was cooled to room temperature and brine was added. The combined organic layers were washed with water and dried over Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4:1) to give compound **6** (3.870 g, 56.6% yield) as a yellow oil: $[\alpha]_D^{26}$ +4.7 (*c* 2.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 6.08–5.94 (m, 1H), 5.74–5.67 (m, 1H), 5.55 (d, J=10.8 Hz, 1H), 4.26–4.20 (m, 1H), 4.10–4.05 (m, 1H), 3.87 (t, J=7.5 Hz, 1H), 3.04 (td, J=10.2 Hz, 4.5 Hz, 1H), 1.42 (s, 3H), 1.37 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 130.38 (t, $J_{C-F}=25.8$ Hz), 121.00 (t, $J_{C-F}=9.5$ Hz), 120.99 (t, $J_{C-F}=227.93$ Hz), 109.35, 73.94, 67.19, 57.72 (t, $J_{C-F}=27.6$ Hz), 26.34, 25.49; ¹⁹F NMR (282 MHz, CDCl₃) δ –106.00 (dm, J=249.3 Hz), -106.82 (dm, J=247.3 Hz); IR (thin film) ν_{max} 3408, 1608, 1065 cm⁻¹; MS (ESI) m/z 208 (M⁺+H). Anal. Calcd for C₉H₁₅NO₂F₂: C, 52.17; H, 7.29; N, 6.76. Found: C, 52.30; H, 7.34; N, 6.31.

3.1.5. [1-(2.2-Dimethyl-[1.3]dioxolan-4-yl)-2.2-difluorobut-3-enyl]-carbamic acid tert-butyl ester (7). A solution of compound 6 (3.870 g, 18.70 mmol) in CH_2Cl_2 (152 mL) was added to di-tert-butyl dicarbonate (20.500 g, 94.04 mmol) dropwise at room temperature with vigorous stirring. After the starting material completely disappeared, water was added to quench the reaction and the mixture was stirred for another 10 min. The organic layer was washed with brine and dried over Na2SO4. After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=8:1) to give compound 7 (5.410 g, 94.3% yield) as a yellow oil: $[\alpha]_{D}^{20} - 32.7$ (c 1.2, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 6.05–5.91 (m, 1H), 5.72 (dd, J=17.4 Hz, 1.2 Hz, 1H), 5.57 (d, J=10.8 Hz, 1H), 4.99 (d, J=10.8 Hz, 1H), 4.49 (t, J=6.6 Hz, 1H), 4.13-4.07 (m, 2H), 3.69-3.63 (m, 1H), 1.45 (s, 9H), 1.44 (s, 3H), 1.37 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 155.74, 130.58 (t, J_{C-F} =17.7 Hz), 121.09 (t, $J_{C-F}=6.2$ Hz), 119.46 (t, $J_{C-F}=184.1$ Hz), 110.00, 80.28, 72.03, 66.86, 54.39 (t, J_{C-F} =21.7 Hz), 28.23, 26.07, 25.33; ¹⁹F NMR (282 MHz, CDCl₃) δ -105.30 (dm, J=248.7 Hz), -107.81 (dm, J=248.7 Hz); IR (thin film) ν_{max} 3458, 3352, 1721, 1503 cm⁻¹; MS m/z330 (M⁺+Na). Anal. Calcd for C₁₄H₂₃NO₄F₂: C, 54.71; H, 7.54; N, 4.56. Found: C, 55.10; H, 7.65; N, 4.13.

3.1.6. [1-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-2,2-difluoro-3,4-dihydroxy-butyl]-carbamic acid tert-butyl esters 8a and 8b. To a solution of compound 7 (5.410 g, 17.62 mmol) in acetone (107 mL) was added NMNO (4.502 g, 33.34 mmol), followed by addition of water (24 mL) at room temperature with stirring. Then, a catalytic amount of OsO_4 (5–10 mol %) solution in water (4% solution) was added. After the reaction mixture was stirred at room temperature for 48 h, the reaction was quenched with saturated aq NaHSO₃ and extracted with ethyl acetate. The combined organic layers were washed with 1 N HCl and brine, and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2:1) to give compound 8a (2.700 g, 46.7% yield) as a white solid and compound 8b (2.101 g, 36.3% yield).

Compound 8a: white solid, mp 91–93 °C; $[\alpha]_D^{23}$ –4.6 (*c* 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 5.32 (d, *J*=9.0 Hz, 1H), 4.58 (td, *J*=6.9 Hz, 1.8 Hz, 1H), 4.18–4.08 (m, 2H), 3.88–3.84 (m, 3H), 3.68 (t, *J*=8.1 Hz, 1H), 1.46 (s, 9H), 1.39 (s, 3H), 1.25 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 157.53, 121.57 (t, *J*_{C-F}=190.9 Hz), 110.25, 81.84, 70.80, 70.18 (dd, *J*_{C-F}=23.6, 18.0 Hz), 67.33, 60.10 (d, *J*_{C-F}=3.4 Hz), 51.32 (dd, *J*_{C-F}=22.9 Hz, 18.0 Hz), 28.20,

26.12, 25.19; ¹⁹F NMR (282 MHz, CDCl₃) δ –122.61 (dm, *J*=254.9 Hz), –123.26 (dm, *J*=255.5 Hz); IR (KBr) ν_{max} 3332, 1710, 1533, 1017 cm⁻¹; MS (ESI) *m/z* 364 (M⁺+Na). Anal. Calcd for C₁₄H₂₅O₆NF₂: C, 49.26; H, 7.38; N, 4.10. Found: C, 49.06; H, 7.17; N, 3.72.

Compound **8b**: white solid, mp 88–91 °C; $[\alpha]_D^{24}$ –25.0 (*c* 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 5.11 (d, *J*=12.6 Hz, 1H), 4.54 (t, *J*=6.3 Hz, 1H), 4.26–4.11 (m, 2H), 4.10–3.85 (m, 3H), 3.68 (t, *J*=7.5 Hz, 3H), 1.46 (s, 12H), 1.38 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ –113.3 (dm, *J*=253.8 Hz), -119.64 (dm, *J*=260.0 Hz); IR (KBr) ν_{max} 3234, 1698, 1513, 1163 cm⁻¹; MS (ESI) *m/z* 364 (M⁺+Na). Anal. Calcd for C₁₄H₂₅O₆NF₂: C, 49.26; H, 7.38; N, 4.10. Found: C, 48.95; H, 7.34; N, 3.83.

3.1.7. Benzoic acid 4-*tert***-butoxycarbonylamino-4-(2,2-dimethyl-[1,3]dioxolan-4-yl)-3,3-difluoro-2-hydroxy-bu-tyl ester (9a).** To a solution of compound **8a** (1.390 g, 4.08 mmol) in anhydrous CH₂Cl₂ (23 mL) and pyridine (9.9 mL) was added BzCl (0.50 mL, 4.08 mmol) in CH₂Cl₂ (3 mL) slowly at -78 °C. After the mixture was stirred at the same temperature for 2 h, MeOH (5 mL) was added and the mixture was stirred for 30 min. Then water was added to quench the reaction. The aqueous layer was extracted with ether. The combined organic layers were washed with 1 N HCl, saturated aq NaHCO₃, and brine, dried over anhydrous Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4:1) to give compound **9a** (1.696 g, 93.5% yield).

Compound **9a**: white solid, mp 90–91 °C; $[\alpha]_{23}^{23}$ –6.0 (*c* 0.9, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.07 (d, *J*=8.4 Hz, 2H), 7.56 (t, *J*=7.2 Hz, 1H), 7.44 (t, *J*=7.8 Hz, 2H), 5.32 (d, *J*=9.3 Hz, 1H), 4.69–4.48 (m, 4H), 4.25–4.14 (m, 3H), 3.70 (t, *J*=7.8 Hz, 1H), 1.47 (s, 12H), 1.40 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 166.53, 157.48, 133.09, 129.93, 129.78, 128.36, 121.49 (t, *J*_{C-F}=192.1 Hz), 110.30, 81.85, 70.86, 68.30 (dd, *J*_{C-F}=23.3 Hz, 17.5 Hz), 67.34, 62.81 (d, *J*_{C-F}=4.5 Hz), 51.27 (dd, *J*_{C-F}=23.3 Hz, 17.4 Hz), 28.20, 26.13, 25.20; ¹⁹F NMR (282 MHz, CDCl₃) δ –121.12 (dd, *J*=256.1 Hz, 25.4 Hz), -123.57 (dd, *J*=255.2 Hz, 24.8 Hz); IR (KBr) ν_{max} 3313, 1733, 1674, 1550, 1450 cm⁻¹; MS (ESI) *m*/*z* 468 (M⁺+Na). Anal. Calcd for C₂₁H₂₉O₇NF₂: C, 56.62; H, 6.56; N, 3.14. Found: C, 56.98; H, 6.64; N, 2.97.

Compound **9***b*: it was prepared using the same condition as described for compound **9***a*; white solid, mp 100–103 °C; $[\alpha]_{D}^{26}$ –22.9 (*c* 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.08–8.05 (m, 2H), 7.58–7.56 (m, 1H), 7.48–7.42 (m, 2H), 5.13 (d, *J*=10.2 Hz, 1H), 4.68–4.56 (m, 3H), 4.34–4.29 (m, 2H), 4.14 (t, *J*=8.4 Hz, 1H), 3.70 (t, *J*=7.5 Hz, 1H), 1.47 (s, 12H), 1.38 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ –110.73 (dm, *J*=260.9 Hz), –119.19 (dm, *J*=267.1 Hz); IR (KBr) ν_{max} 3494, 3382, 1707, 1506, 717 cm⁻¹; MS (ESI) *m/z* 468 (M⁺+Na). Anal. Calcd for C₂₁H₂₉O₇NF₂: C, 56.62; H, 6.56; N, 3.14. Found: C, 56.13; H, 6.72; N, 2.78.

3.1.8. Benzoic acid 4*-tert*-butoxycarbonylamino-3,3-difluoro-5-hydroxy-tetrahydrofuran-2-ylmethyl ester (11a). A mixture of compound 9a (1.120 g, 2.52 mmol)

and 75% of aq AcOH (13 mL) was stirred at 50 °C for 3 h. The solvent was then removed in vacuo. The residue was dissolved in acetone (11 mL), followed by treatment with a solution of NaIO₄ (0.810 g, 3.78 mmol) in water (13 mL) at room temperature with stirring. After stirring for 3 h, the mixture was filtered and the filtrate was washed with acetone. The solvent was removed in vacuo and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried over anhydrous Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was dissolved in MeOH (20 mL). To the solution of compound 10a was added NaBH₄ (0.187 g, 5.00 mmol) in portions at 0 °C. After stirring for 20 min, 75% of aq AcOH was added until no gas was produced. The resulting mixture was extracted with ethyl acetate. The combined organic layer was washed with saturated NaHCO₃ solution, brine, dried over anhydrous Na₂SO₄, filtered, and the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2:1) to give 0.730 g of compound 11a (77.3% yield, three steps).

Compound 11a: white solid, mp 106–110 °C; $[\alpha]_{D}^{26}$ +8.7 (c 0.8, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.08–8.05 (m, 2H), 7.59–7.54 (m, 1H), 7.47–7.41 (m, 2H), 5.52 (d, J=8.1 Hz, 1H), 5.01 (br, 1H), 4.71–4.67 (m, 1H), 4.52–4.46 (m, 1H), 4.22–4.11 (m, 3H), 3.87–3.85 (m, 1H), 1.75 (br, 1H), 1.47 (s, 9H); ¹⁹F NMR (282 MHz, CDCl₃) δ –121.29 (dd, J=253.8 Hz, 25.1 Hz), –122.76 (dd, J=253.2 Hz, 23.1 Hz); IR (KBr) ν_{max} 3286, 1728, 1680, 1557, 713 cm⁻¹; MS (ESI) *m*/*z* 398 (M⁺+Na). Anal. Calcd for C₁₇H₂₃O₆NF₂: C, 54.39; H, 6.18; N, 3.73. Found: C, 54.45; H, 6.17; N, 3.18.

Compound **11b**: it was prepared using the same condition as described for compound **11a**; white solid, mp 84–86 °C; $[\alpha]_{26}^{26}$ –7.2 (*c* 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.06–8.03 (m, 2H), 7.58–7.54 (m, 1H), 7.45–7.40 (m, 2H), 5.35 (d, *J*=9.3 Hz, 1H), 4.68–4.52 (m, 2H), 4.35–4.29 (m, 2H), 3.94–3.76 (m, 2H), 1.44 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ 166.84, 156.18, 133.18, 129.66, 129.42, 128.28, 121.52 (t, *J*_{C-F}=191.8 Hz), 80.70, 69.51 (t, *J*_{C-F}=21.2 Hz), 63.70, 60.03, 53.65 (t, *J*_{C-F}=16.2 Hz), 28.10; ¹⁹F NMR (282 MHz, CDCl₃) δ –113.16 (dm, *J*=260.0 Hz), –118.90 (dm, *J*=234.1 Hz); IR (KBr) ν_{max} 3367, 1704, 1278, 713 cm⁻¹; MS (ESI) *m/z* 398 (M⁺+Na), 414 (M⁺+K). Anal. Calcd for C₁₇H₂₃O₆NF₂: C, 54.39; H, 6.18; N, 3.73. Found: C, 54.52; H, 6.13; N, 3.42.

3.1.9. Benzoic acid 4-*tert***-butoxycarbonylamino-3,3-di-fluoro-tetrahydro-thiophen-2-ylmethyl ester (12a).** To a solution of compound **11a** (0.730 g, 1.95 mmol) in anhydrous CH₂Cl₂ (6 mL) and pyridine (5.7 mL) was added MsCl (0.62 mL, 7.79 mmol) slowly at 0 °C. The reaction mixture was then warmed to room temperature and stirred overnight. The reaction was quenched with water. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with 1 N HCl, saturated aq NaHCO₃, water, and brine, dried over anhydrous Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was dissolved in DMF (24 mL) and Na₂S·9H₂O (0.700 g, 2.93 mmol) was added. Then, the reaction mixture was heated to 80 °C. After stirring for 20 min, the reaction mixture was added.

The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous Na_2SO_4 . After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=6:1) to give compound **12a** (0.468 g, 64.5% yield, two steps).

Compound **12a**: white solid, mp 94–95 °C; $[\alpha]_{D}^{25}$ –72.2 (*c* 0.7, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.06 (d, *J*=8.1 Hz, 2H), 7.61–7.55 (m, 1H), 7.48–7.43 (m, 2H), 4.99 (d, *J*=7.8 Hz, 1H), 4.63–4.57 (m, 2H), 4.44 (dd, *J*=11.7 Hz, 6.0 Hz, 1H), 3.88–3.80 (m, 1H), 3.17–3.11 (m, 1H), 2.67 (t, *J*=9.6 Hz, 1H), 1.46 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ 165.97, 154.84, 133.28, 129.79, 129.53, 128.48, 126.21 (dd, *J*_{C–F}=175.5 Hz, 152.3 Hz), 80.71, 63.19, 55.78 (t, *J*_{C–F}=13.7 Hz), 45.13 (t, *J*_{C–F}=16.5 Hz, 12.8 Hz), 29.10, 28.25; ¹⁹F NMR (282 MHz, CDCl₃) δ –109.54 (dm, *J*=234.9 Hz), –115.87 (dm, *J*=234.6 Hz); IR (KBr) ν_{max} 3368, 1729, 1696, 1523, 1283, 709 cm⁻¹; MS (ESI) *m/z* 391 (M⁺+NH₄). Anal. Calcd for C₁₇H₂₁O₄NSF₂: C, 54.68; H, 5.67; N, 3.75. Found: C, 54.85; H, 5.81; N, 3.63.

Compound 12b: it was prepared using the same condition as described for compound **12a**; white solid, mp 116–118 °C; $[\alpha]_D^{26}$ +41.9 (c 0.7, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.05-8.02 (m, 2H), 7.60-7.55 (m, 1H), 7.47-7.41 (m, 2H), 4.97 (d, J=8.7 Hz, 1H), 4.67-4.60 (m, 2H), 4.51-4.45 (m, 2H), 4.06–3.92 (m, 1H), 3.08 (t, J=10.2 Hz, 1H), 2.77 (t, J=10.2 Hz, 1H), 1.46 (s, 9H); ¹³C NMR (75.5 MHz, CDCl₃) δ 165.92, 154.81, 133.26, 129.76, 129.55, 128.44, 124.65 (dd, J_{C-F} =196.5 Hz, 189.3 Hz), 80.76, 62.42 (d, J_{C-F} =8.0 Hz), 56.65 (t, J_{C-F} =16.4 Hz), 44.10 (t, $J_{C-F}=17.1$ Hz), 29.14 (d, $J_{C-F}=4.8$ Hz), 28.24; ¹⁹F NMR (282 MHz, CDCl₃) δ -109.21 (dm, J= 231.2 Hz), -125.85 (dm, J=231.0 Hz); IR (KBr) ν_{max} 3369, 1730, 1695, 1529, 708 cm⁻¹; MS (ESI) m/z 396 (M^++Na) , 391 (M^++NH_4) . Anal. Calcd for $C_{17}H_{21}O_4NSF_2$: C, 54.68; H, 5.67; N, 3.75. Found: C, 54.66; H, 5.56; N, 3.59.

3.1.10. Benzoic acid 4-amino-3,3-difluoro-tetrahydrothiophen-2-ylmethyl ester (13a). Trifluoroacetic acid (4 mL) was added in one portion to a solution of compound **12a** (0.373 g, 1.23 mmol) in CH₂Cl₂ (8 mL). The reaction mixture was stirred at room temperature for 15 min. Volatiles were evaporated and the residue was dissolved in ether and washed with NaHCO₃. The aqueous layer was extracted with ether. The combined organic layers were dried over Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was purified by silica gel column chromato-graphy (petroleum ether/ethyl acetate=2:1) to give compound **13a** (0.322 g, 95.6% yield).

Compound 13a: clear oil, $[\alpha]_{D}^{20}$ –102.5 (*c* 0.5, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.05–8.02 (m, 2H), 7.60– 7.55 (m, 1H), 7.45 (t, *J*=7.8 Hz, 2H), 4.64–4.58 (m, 1H), 4.48–4.42 (m, 1H), 4.00–3.88 (m, 1H), 3.67–3.65 (m, 1H), 3.12 (dd, *J*=11.4 Hz, 6.3 Hz, 1H), 2.67–2.61 (m, 1H), 1.55 (s, 2H); ¹³C NMR (75.5 MHz, CDCl₃) δ 165.97, 133.24, 129.71, 129.65, 128.46, 127.34 (t, *J*_{C-F}=193.7 Hz), 63.10 (dd, *J*_{C-F}=5.7 Hz, 2.4 Hz), 57.89 (dd, *J*_{C-F}=21.3 Hz, 17.9 Hz), 45.11 (dd, *J*_{C-F}=20.3 Hz, 16.5 Hz), 31.27 (t, $J_{C-F}=2.3$ Hz); ¹⁹F NMR (282 MHz, CDCl₃) δ -114.08 (dm, J=233.8 Hz), -116.77 (dm, J=233.5 Hz); IR (KBr) ν_{max} 3394, 1720, 1273, 713 cm⁻¹; MS (ESI) *m*/*z* 274 (M⁺+H), 291 (M⁺+NH₄).

Compound **13b**: it was prepared using the same condition as described for compound **13a**; clear oil, $[\alpha]_D^{24}$ +14.7 (*c* 0.5, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.05–8.02 (m, 2H), 7.59–7.54 (m, 1H), 7.46–7.41 (m, 2H), 4.70–4.63 (m, 1H), 4.52–4.46 (m, 1H), 3.99–3.90 (m, 1H), 3.62 (br, 1H), 2.99 (t, *J*=9.9 Hz, 1H), 2.72 (t, *J*=10.5 Hz, 1H), 1.55 (s, 2H); ¹³C NMR (75.5 MHz, CDCl₃) δ 165.88, 133.12, 129.64, 129.58, 128.34, 125.13 (t, *J*_{C-F}=188.0 Hz), 62.80 (d, *J*_{C-F}=7.4 Hz), 58.96 (t, *J*_{C-F}=18.8 Hz), 44.77 (t, *J*_{C-F}=18.0 Hz), 30.99 (t, *J*_{C-F}=4.5 Hz); ¹⁹F NMR (282 MHz, CDCl₃) δ –110.09 (dm, *J*=222.5 Hz), -129.67 (dm, *J*= 219.1 Hz); IR (thin film) ν_{max} 3394, 1720, 1452, 1278, 1115 cm⁻¹; MS (ESI) *m/z* 274 (M⁺+H).

3.1.11. Benzoic acid 4-[3-(3-ethoxy-acryloyl)-ureido]-3,3diffuoro-tetrahydro-thiophen-2-ylmethyl ester (14a). To a solution of compound **13a** (0.060 g, 0.22 mmol) in DMF (3 mL) at -25 °C, a solution of 3-ethoxy-2-propenoyl isocyanate (0.059 g, 0.42 mmol) in benzene (1.6 mL) was added slowly enough to cause no rise in temperature. After addition, the reaction mixture was stirred overnight at room temperature. EtOH and toluene were then added to form a low-boiling ternary azeotrope that was evaporated under reduced pressure while the temperature was maintained below 40 °C. The solid residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate= 3:1) to give compound **14a** (0.125 g, 82.4% yield).

Compound 14*a*: white solid, mp 146–148 °C; $[\alpha]_{D}^{26}$ –76.4 (*c* 0.9, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 9.37 (d, J=8.7 Hz, 1H), 9.13 (s, 1H), 8.06 (d, J=8.1 Hz, 2H), 7.68 (d, J=11.7 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.45 (t, J=7.2 Hz, 2H), 5.28 (d, J=12.0 Hz, 1H), 4.93-4.88 (m, 1H), 4.64 (dd, J=11.7 Hz, 6.3 Hz, 1H), 4.45 (dd, J=11.7 Hz, 6.0 Hz, 1H), 3.95-3.87 (m, 3H), 3.20 (dd, J=10.5 Hz, 6.9 Hz, 1H), 2.80 (t, J=8.4 Hz, 1H), 1.33 (t, J=6.9 Hz, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 168.29, 165.93, 163.64, 155.08, 133.32, 129.78, 129.49, 128.50, 126.39 (dd, J_{C-F}=195.7 Hz, 192.4 Hz), 97.55, 67.75, 62.92 (d, $J_{C-F}=8.0$ Hz), 55.09 (dd, $J_{C-F}=22.3$ Hz, 16.1 Hz), 45.28 (dd, $J_{C-F}=20.5$ Hz, 16.1 Hz), 29.35 (t, $J_{C-F}=2.6$ Hz), 14.43; ¹⁹F NMR (282 MHz, CDCl₃) δ -109.34 (dm, J=234.9 Hz), -115.17 (dm, J=234.6 Hz); IR (KBr) $v_{\rm max}$ 3242, 1738, 1706, 1677, 1541 cm⁻¹; MS (ESI) m/z 415 (M⁺+H), 437 (M⁺+Na).

Compound **14b**: it was prepared using the same condition as described for compound **14a**; white solid, mp 150–153 °C; $[\alpha]_{D}^{27}$ –13.1 (*c* 0.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 9.32 (d, *J*=8.7 Hz, 1H), 9.23 (s, 1H), 8.05–8.02 (m, 2H), 7.67 (d, *J*=12.3 Hz, 1H), 7.60–7.54 (m, 1H), 7.47–7.41 (m, 2H), 5.30 (d, *J*=12.3 Hz, 1H), 4.93–4.81 (m, 1H), 4.08–3.95 (m, 3H), 3.11 (dd, *J*=10.2 Hz, 6.9 Hz, 1H), 2.91 (t, *J*=10.8 Hz, 1H), 1.35 (t, *J*=6.9 Hz, 3H); ¹³C NMR (75.5 MHz, CDCl₃) δ 168.18, 165.90, 163.64, 154.94, 133.23, 129.73, 129.51, 128.39, 124.75 (t, *J*_{C–F}=195.5 Hz), 97.63, 67.97, 62.44 (d, *J*_{C–F}=7.9 Hz), 55.61 (t,

 $\begin{array}{l} J_{\rm C-F}{=}15.6~{\rm Hz}), \ 44.35~({\rm t}, \ J_{\rm C-F}{=}17.6~{\rm Hz}), \ 29.14~({\rm d}, \ J_{\rm C-F}{=}\\ 4.8~{\rm Hz}), \ 14.47; \ {}^{19}{\rm F}~{\rm NMR}~(282~{\rm MHz},~{\rm CDCl}_3)~\delta~{-}107.82\\ ({\rm dm}, \ J{=}231.5~{\rm Hz}), \ -124.50~({\rm dm}, \ J{=}231.5~{\rm Hz}); ~{\rm IR}~({\rm KBr})\\ \nu_{\rm max}~3248, \ 1697, \ 1683, \ 1620, \ 1270, \ 715~{\rm cm}^{-1}; ~{\rm MS}~({\rm ESI})\\ m/z ~~415~({\rm M}^+{\rm H}), \ 437~({\rm M}^+{\rm Ha}). ~{\rm Anal.}~{\rm Calcd}~{\rm for}\\ {\rm C}_{18}{\rm H}_{20}{\rm O}_5{\rm N}_2{\rm SF}_2:~{\rm C}, \ 52.17;~{\rm H}, \ 4.86;~{\rm N}, \ 6.76.~{\rm Found:}~{\rm C},\\ 52.73;~{\rm H}, \ 4.79;~{\rm N}, \ 6.40. \end{array}$

3.1.12. 1-(4,4-Difluoro-5-hydroxymethyl-tetrahydrothiophen-3-yl)-1*H*-pyrimidine-2,4-dione (1a). A solution of compound 14a (0.125 g, 0.30 mmol) in dioxane (2 mL) and 2 N sulfuric acid (5 mL) was refluxed for 3 h. The mixture was cooled to room temperature and neutralized by diluted aq NaOH. The mixture was extracted by ethyl acetate. The organic layers were dried over Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was dissolved in saturated solution of ammonia in methanol (8 mL) and stirred overnight at room temperature. The solvent was removed and the residue was purified by silica gel column chromatography (dichloromethane/methanol= 35:1) to give compound 1a (0.063 g, 79.0% yield, two steps).

Compound Ia: white solid, mp 86–88 °C; $[\alpha]_{26}^{26}$ –48.3 (*c* 0.4, CH₃OH); ¹H NMR (300 MHz, CD₃OD) δ 7.69 (d, *J*=8.1 Hz, 1H), 5.63 (d, *J*=8.1 Hz, 1H), 5.59–5.49 (m, 1H), 3.70–3.68 (m, 2H), 3.58–3.48 (m, 1H), 3.21–3.02 (m, 3H); ¹³C NMR (75.5 MHz, CD₃OD) δ 165.92, 152.99, 144.18 (d, *J*_{C-F}=3.4 Hz), 127.96 (dd, *J*_{C-F}=157.0 Hz, 152.4 Hz), 103.39, 62.28 (t, *J*_{C-F}=3.2 Hz), 59.27 (dd, *J*_{C-F}=17.4 Hz, 11.6 Hz), 50.71 (dd, *J*_{C-F}=14.9 Hz, 12.6 Hz), 26.37 (d, *J*_{C-F}=4.1 Hz); ¹⁹F NMR (282 MHz, CD₃OD) δ –106.14 (dm, *J*=232.9 Hz), -116.41 (dm, *J*=230.7 Hz); IR (KBr) ν_{max} 3384, 1730, 1386, 1095 cm⁻¹; MS (ESI) *m/z* 265 (M⁺+H), 282 (M⁺+NH₄), 287 (M⁺+Na).

Compound 1*b*: it was prepared using the same condition as described for compound 1*a*; white solid, mp 206–214 °C; $[\alpha]_{D}^{28}$ +88.4 (*c* 0.2, CH₃OH); ¹H NMR (300 MHz, CD₃OD) δ 7.80 (dd, *J*=8.1 Hz, 2.7 Hz, 1H), 5.74 (d, *J*=8.4 Hz, 1H), 5.70–5.58 (m, 1H), 4.05–3.99 (m, 1H), 3.92–3.87 (m, 1H), 3.84–3.68 (m, 1H), 3.43–3.36 (m, 1H), 3.14–3.08 (m, 1H); ¹³C NMR (75.5 MHz, CD₃OD) δ 165.87, 152.97, 144.04 (d, *J*_{C-F}=4.4 Hz), 126.79 (dd, *J*_{C-F}=195.3 Hz, 191.1 Hz), 103.29, 61.88 (d, *J*_{C-F}=7.6 Hz), 59.56 (dd, *J*_{C-F}=20.3 Hz, 14.7 Hz), 49.23 (t, *J*_{C-F}=17.2 Hz), 26.78 (t, *J*_{C-F}=5.4 Hz); ¹⁹F NMR (282 MHz, CD₃OD) δ –109.63 (dm, *J*=230.4 Hz), -125.00 (dm, *J*=229.0 Hz); IR (KBr) ν_{max} 3386, 3172, 1718, 1667, 1383 cm⁻¹; MS (ESI) *m*/z 265 (M⁺+H), 287 (M⁺+Na).

3.1.13. 4-Amino-1-(4,4-difluoro-5-hydroxymethyl-tetrahydro-thiophen-3-yl)-1*H***-pyrimidin-2-one (1d). To a solution of compound 1b (0.020 g, 0.076 mmol) in pyridine (2 mL), DMAP (0.002 g, 0.016 mmol) and Ac₂O (0.20 mL, 1.59 mmol) were added. After being stirred for 12 h, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layers were combined and washed with 1 N HCl, saturated aq NaHCO₃, brine, dried over anhydrous Na₂SO₄. After filtration and removal of the solvent in vacuo, the residue was dissolved in CH₃CN (2 mL) at 0 °C. After that, TPSCl (0.042 g, 0.14 mmol), DMAP (0.017 g, 0.14 mmol), and Et₃N (0.019 g, 0.14 mmol) were added.** and stirred for 4 h. After that concd $NH_3 \cdot H_2O(28\%, 1 \text{ mL})$ was added and the whole reaction mixture kept stirring overnight. Then, the solvent was removed and the residue was purified by silica gel column chromatography (dichloromethane/methanol=10:1) to give compound **1d** (0.010 g, 50.2% yield, three steps).

Compound 1d: white solid, mp 234–238 °C; $[\alpha]_D^{27}$ +90.1 (*c* 0.6, CH₃OH); ¹H NMR (300 MHz, CD₃OD) δ 7.66 (dd, *J*=7.8 Hz, 2.4 Hz, 1H), 5.82 (d, *J*=7.5 Hz, 1H), 5.79–5.62 (m, 1H), 3.91 (dd, *J*=11.4 Hz, 6.3 Hz, 1H), 3.80–3.75 (m, 1H), 3.72–3.69 (m, 1H), 3.62–3.50 (m, 1H), 3.00–2.94 (m, 1H); ¹³C NMR (75.5 MHz, CD₃OD) δ 167.64, 158.81, 144.50 (d, *J*_{C-F}=4.9 Hz), 126.77 (dd, *J*_{C-F}=195.4 Hz, 190.8 Hz), 96.74, 64.62, 61.95 (d, *J*_{C-F}=7.9 Hz), 60.02 (dd, *J*_{C-F}=20.1 Hz, 14.6 Hz), 27.24 (d, *J*_{C-F}=5.4 Hz); ¹⁹F NMR (282 MHz, CD₃OD) δ –109.49 (dm, *J*=229.3 Hz), -124.91 (dm, *J*=229.3 Hz); IR (KBr) ν_{max} 3398, 1663, 1181, 1016 cm⁻¹; MS (ESI) *m/z* 264 (M⁺+H).

Compound Ic: it was prepared using the same condition as described for compound **1d**; white solid, mp 210–214 °C; $[\alpha]_{D}^{29}$ –27.6 (*c* 0.2, CH₃OH); ¹H NMR (300 MHz, CD₃OD) δ 7.69 (dd, *J*=7.5 Hz, 2.1 Hz, 1H), 5.85 (d, *J*= 7.5 Hz, 1H), 5.79–5.64 (m, 1H), 3.75–3.66 (m, 2H), 3.61–3.50 (m, 1H), 3.14–3.02 (m, 2H); ¹³C NMR (75.5 MHz, CD₃OD) δ 167.66, 158.85, 144.67 (d, *J*_{C-F}=4.2 Hz), 128.04 (dd, *J*_{C-F}=195.9 Hz, 190.6 Hz), 96.83, 62.55 (t, *J*_{C-F}=4.0 Hz), 59.78 (dd, *J*_{C-F}=21.7 Hz, 14.6 Hz), 50.90 (dd, *J*_{C-F}=18.6 Hz, 15.5 Hz), 26.89 (d, *J*_{C-F}=5.3 Hz); ¹⁹F NMR (282 MHz, CD₃OD) δ –106.29 (dm, *J*=231.8 Hz), –116.35 (dm, *J*=230.1 Hz); IR (KBr) ν_{max} 3419, 1659, 1499, 1395 cm⁻¹; MS (ESI) *m/z* 264 (M⁺+H).

Acknowledgements

National Natural Science Foundation of China, Ministry of Education of China, and Shanghai Municipal Scientific Committee are greatly acknowledged for funding this work.

References and notes

- (a) De Clercq, E. Adv. Drug Res. 1988, 17, 1; (b) Mitsuya, H.; Broder, S. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1911; (c) Mansuri, M. M.; Starett, J. E.; Ghazzouli, L.; Hitchcock, M. J. M.; Sommadossi, J. P.; Martin, J. C. J. Med. Chem. 1989, 32, 4; (d) Yarchoan, R.; Mitsuya, H.; Thomas, R. V.; Pluda, J. M.; Hartman, N. R.; Perno, C. F.; Marczyk, K. S.; Allain, J. P.; Johns, D. G.; Broder, S. Science 1989, 245, 412.
- Yoshimura, Y.; Endo, M.; Miura, S.; Sakata, S. J. Org. Chem. 1999, 64, 7912.
- Wang, P.; Hong, J. H.; Cooperwood, J. S.; Chu, C. K. Antiviral Res. 1998, 40, 19.
- Young, R. J.; Shaw-Ponter, S.; Thomson, J. B.; Miller, J. A.; Cumming, J. G.; Pugh, A. W.; Rider, P. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2599.
- (a) York, J. L. J. Org. Chem. 1981, 46, 2171; (b) Marquez, V. E.; Lim, M.-I. Med. Res. Rev. 1986, 6, 1; (c) Marquez, V. E.; Tseng, C. K.-H.; Kelley, J. A.; Mitsuya, H.; Broder, S.; Roth, J. S.; Driscoll, J. S. Biochem. Pharmacol. 1987, 36, 2719; (d) Kawaguchi, T.; Fukushima, S.; Ohmura, M.; Mishima, M.;

Nakano, M. Chem. Pharm. Bull. **1989**, 37, 1944; (e) Nair, V.; Buenger, G. S. J. Org. Chem. **1990**, 55, 3695.

- 6. (a) De Clercq, E. Nucleosides Nucleotides 1994, 13, 1271; (b) De Clercq, E. J. Med. Chem. 1995, 38, 2491; (c) Saunders, J.; Cameron, J. M. Med. Res. Rev. 1995, 15, 497; (d) Mansour, T. S. Expert Opin. Ther. Pat. 1996, 6, 137; (e) Marquez, V. Adv. Antiviral Drug Des. 1996, 2, 89; (f) Agrofoglio, L.; Suhas, E.; Farese, A.; Condom, R.; Challand, S. R.; Earl, R. A.; Guedj, R. Tetrahedron 1994, 50, 10611; (g) Freeman, S.; Gardiner, J. M. Mol. Biotechnol. 1996, 5, 125; (h) Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J.; Neyts, J.; De Clercq, E. Antiviral Chem. Chemother. 1997, 8, 1; (i) Mansour, T. S.; Storer, R. Curr. Pharm. Des. 1997, 3, 227.
- (a) Chang, C. N.; Doong, S. L.; Zhou, J. H.; Beach, J. W.; Jeong, L. S.; Chu, C. K.; Tasi, C. H.; Cheng, Y. C. J. Biol. Chem. 1992, 267, 13938; (b) Doong, S. L.; Tasi, C. H.; Schinazi, R. F.; Liotta, D. C.; Cheng, Y. C. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8495.
- (a) Frick, L. W.; Lambe, C. U.; St. John, L.; Taylor, L. C.; Nelson, D. J. *Antimicrob. Agents Chemother.* **1994**, *38*, 2722;
 (b) Frick, L. W.; St. John, L.; Taylor, L. V.; Painter, G. R.;

Furman, P. A.; Liotta, D. C.; Furfine, E. S.; Nelson, D. J. Antimicrob. Agents Chemother. 1993, 37, 2285.

- (a) Blackburn, G. M.; England, D. A.; Kolkmann, F. J. Chem. Soc., Chem. Commun. 1981, 930; (b) Blackburn, G. M.; Brown, D.; Martin, S. J. J. Chem. Res., Synop. 1985, 92; (c) Blackburn, G. M.; Eckstein, F.; Kent, D. E.; Perree, T. D. Nucleosides Nucleotides 1985, 4, 165; (d) Blackburn, G. M.; Kent, D. E. J. Chem. Soc., Perkin Trans. 1 1986, 913; (e) Blackburn, G. M.; Peree, T. D.; Rashid, A.; Bisbal, C.; Lebleu, B. Chem. Scr. 1986, 26, 21; (f) Blackburn, G. M.; Brown, D.; Martin, S. J.; Parratt, M. J. J. Chem. Soc., Perkin Trans. 1 1987, 181.
- Wu, Y.-Y.; Zhang, X.; Meng, W.; Qing, F.-L. Org. Lett. 2004, 6, 3941.
- 11. Shaw, G.; Warrener, R. N. J. Chem. Soc. 1958, 157.
- Zhang, X.; Xia, H.; Dong, X.; Jin, J.; Meng, W.; Qing, F.-L. J. Org. Chem. 2003, 68, 9026.
- Xu, X.-H.; Qiu, X.-L.; Zhang, X.; Qing, F.-L. J. Org. Chem. 2006, 71, 2820.
- Crystal data have been deposited at the Cambridge Crystallographic Data Center with reference numbers: compound 1a, CCDC 628402; compound 1b, CCDC 628403.